

## €1.1 million in funding granted jointly by Bpifrance and the Bourgogne Franche- Comté region

Dijon, 4 February 2019

**CROSSJECT (ISIN: FRO011716265; Ticker: ALCJ), a specialty pharma company developing and soon to market a portfolio of drugs for use in emergency situations,** announces that it has obtained €1.1 million in funding from Bpifrance and the Bourgogne Franche-Comté regional authority.

Patrick Alexandre, CEO of Crossject, said: *“Nearly two months after the success of our capital increase, the grant of this – non-dilutive – funding is another positive step forward for Crossject. It will enable us to increase and secure our production capacities and continue to create jobs in Bourgogne Franche-Comté. On behalf of Crossject, I thank Bpifrance and the Bourgogne Franche-Comté regional authority for their support of our strategy of developing drugs for use in emergency situations.”*

Bpifrance, the French public investment bank, and the Bourgogne-Franche-Comté regional authority have just jointly awarded Crossject an R&D Innovation Loan and a Zero-Rate Innovation Loan in a total amount of €1.1 million over eight years, with a grace period of three years. The loans are intended to support the ramp-up of pyrotechnic production capacity. They provide Crossject with additional financial resources to bring technological and automation improvements to its production lines located in Gray (manufacture of the gas generator and assembly of the ZENEO® actuator) and to support future growth related to the marketing of ZENEO®.



## Contacts:

Crossject  
Patrick Alexandre  
[info@crossject.com](mailto:info@crossject.com)

Investor relations  
CM-CIC Market Solutions  
Catherine Couanau +33 (0)1 53 48 81 97  
[catherine.couanau@cmcic.fr](mailto:catherine.couanau@cmcic.fr)

Press relations  
Buzz & Compagnie  
Mélanie Voisard +33 (0)3 80 43 54 89  
[melanie.voisard@buzzetcompagnie.com](mailto:melanie.voisard@buzzetcompagnie.com)  
Audrey Lachat +33 (0)3 80 43 54 89  
[audrey.lachat@buzzetcompagnie.com](mailto:audrey.lachat@buzzetcompagnie.com)

## About CROSSJECT • [www.crossject.com](http://www.crossject.com)

Crossject (ISIN: FR0011716265; Ticker: ALCJ; LEI: 969500W1VTFNL2D85A65) is developing and is soon to market a portfolio of drugs dedicated to emergency situations: epilepsy, overdose, allergic shock, severe migraine and asthma attack. Thanks to its patented needle-free self-injection system, Crossject aims to become the world leader in self-administered emergency drugs. The company has been listed on the Euronext Growth market in Paris since 2014, and benefits from Bpifrance funding.

## Disclaimer

This press release may contain forward-looking information. This information is based either on trends or objectives, and should not be taken as a forecast of future performance or any other performance indicator. This information is inherently subject to risks and uncertainties, which may in certain cases be beyond the company's control, particularly in the context of an R&D process. A more detailed description of these risks and uncertainties can be found in the company's annual financial report, which is available on its website ([www.crossject.com](http://www.crossject.com)).

Translation for information purposes only. In case of discrepancy between the French and English versions of this press release, only the French version should be deemed valid.